Iomeprol

Hypersensitivity. Multiple myeloma, Waldenstroem’s paraproteinaemia. Intrathecal concomitant administration with corticosteroid. Severe hepatic and renal impairment.

Patient with asthma, history of allergy, heart failure, coronary artery disease, diabetes mellitus, hyperthyroidism or goitre, myasthenia gravis, cerebral infarction, acute intracranial haemorrhage, conditions involving blood-brain barrier damage, brain oedema, acute demyelination, intracranial tumours or metastases, history of epilepsy, cerebrovascular disease, acute and chronic alcoholism, drug addiction, phaeochromocytoma, sickle cell disease. Moderate renal and hepatic impairment. Neonates, infants and children. Pregnancy and lactation.

Significant: Myelomatosis or paraproteinaemias, pulmonary oedema, haemodynamic changes, ischaemic ECG changes, arrhythmias, convulsive seizures, exacerbation of myasthenia, neurological complications, vasospasm, cerebral ischaemic phenomena, anxiety, excitement, pain.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, diarrhoea, taste disturbance.
General disorders and administration site conditions: Injection site pain, chest pain, heat sensation.
Musculoskeletal and connective tissue disorders: Back pain.
Nervous system disorders: Headache, dizziness.
Respiratory, thoracic and mediastinal disorders: Dyspnoea.
Skin and subcutaneous tissue disorders: Erythema, urticaria, pruritus.
Vascular disorders: Flushing, hypertension.
Potentially Fatal: Severe anaphylactoid and CV reactions (e.g. severe hypotension, tachycardia, dyspnoea, cardiac arrest).

This drug may cause delayed reactions, if affected, do not drive or operate machinery.

Monitor electrolyte fluid balance prior to administration; renal function. Maintain hydration prior and during the procedure.

Symptoms: Life-threatening pulmonary and CV adverse reactions. Management: Symptomatic and supportive treatment.

Risk of bronchospasm with β-blockers. Reduced seizure threshold with neuroleptics and antidepressants (e.g. MAO inhibitors, TCA, analeptics, anti-emetics phenothiazines); discontinue for 48 hours before and resume 24 hours after the procedure. Increased risk of lactic acidosis with concomitant use of metformin; discontinue prior to procedure and withhold for 48 hours after the procedure.
Potentially Fatal: Concurrently administered corticosteroids may promote and affect the signs and symptoms of arachnoiditis (intrathecal).

May interfere with thyroid function tests; bilirubin, proteins, Fe, copper, Ca, phosphate tests.

Description:
Mechanism of Action: Iomeprol is a nonionic iodinated contrast medium used in radiographic procedures including myelography, urography, arthrography and computed tomography.
Pharmacokinetics:
Absorption: Completely absorbed from the cerebrospinal fluid (intrathecal).
Excretion: Via urine (50%, as unchanged drug). Terminal elimination half-life: 1.9 hours; 8-11 hours (intrathecal).

Source: National Center for Biotechnology Information. PubChem Database. Iomeprol, CID=3731, https://pubchem.ncbi.nlm.nih.gov/compound/Iomeprol (accessed on Jan. 21, 2020)

Store below 30°C. Protect from light.

Các tác nhân dùng trong chẩn đoán hình ảnh & các chẩn đoán khác

V08AB10 - iomeprol ; Belongs to the class of watersoluble, nephrotropic, low osmolar preparations used as X-ray contrast media.

Anon. Iomeprol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 30/01/2018.

Buckingham R (ed). Iomeprol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 30/01/2018.

Regional Health Limited. Iomeron Solution for Injection data sheet 28 July 2006. Medsafe. http://www.medsafe.govt.nz/. Accessed 30/01/2018.